Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NIPA: Naloxegol to prevent opioid-induced GI motility disturbance in brain-injured patients
2019-000959-14Phase 3Active
- Sponsor
- Centre Hospitalier Universitaire de Brest
- Start
- Dec 2020
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of naloxegol in Gastrointestinal Dysmotility and opioid-induced constipation (OIC) (2 arms), sponsored by Centre Hospitalier Universitaire de Brest. Started Dec 2020; status: active.
02
Drugs
naloxegol
03
Conditions
Gastrointestinal Dysmotilityopioid-induced constipation (OIC)
Beyond the preview
Go deeper on 2019-000959-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000959-14.